Stapokibart clinical trials
Also written CM310.
How each study uses stapokibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the stapokibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2023 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 7
Keymed Biosciences Co.Ltd (24) · Chengdu Kangnuoxing Biopharma,Inc. (3) · Beijing Tongren Hospital (3) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Huazhong University of Science and Technology (1) · First Affiliated Hospital of Chongqing Medical University (1) · Beijing Friendship Hospital (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test stapokibart, phase 3 first.
- Dec 2026Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisPhase 3 · Chengdu Kangnuoxing Biopharma,Inc.
- Feb 2027A Study of Stapokibatrt in Children Subjects With Atopic DermatitisPhase 3 · Keymed Biosciences Co.Ltd
- Dec 2026Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia SyndromeNot applicable · Huazhong University of Science and Technology
- Dec 2026Efficacy and Safety of Stapokibart for Primary Cutaneous AmyloidosisNot applicable · First Affiliated Hospital of Chongqing Medical University
- Jun 2027Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCPhase 1 · Beijing Tongren Hospital
Studies
Open first, then newest update. How each study uses stapokibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 36
- Study on the Treatment of Adolescent Patients With Seasonal Allergic RhinitisRecruitingPhase 3Chengdu Kangnuoxing Biopharma,Inc.NCT07678931Written as Stapokibart
- A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory LymphomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07791615Written as Stapokibart, immune checkpoint inhibitor
- Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)Not yet recruitingPhase 2Chengdu Kangnuoxing Biopharma,Inc.NCT07617324Written as Stapokibart injection
- Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal PolypsNot yet recruitingNot applicableBeijing Tongren HospitalNCT07616609Written as Stapokibart
- Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCRecruitingPhase 1Beijing Tongren HospitalNCT07040072Written as Stapokibart and Finotonlimab
- Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia SyndromeNot yet recruitingNot applicableHuazhong University of Science and TechnologyNCT07240376Written as Stapokibart (CM310)
- Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous PemphigoidNot yet recruitingPhase 3Chengdu Kangnuoxing Biopharma,Inc.NCT07210554Written as Stapokibart injection
- Efficacy and Safety of Stapokibart for Primary Cutaneous AmyloidosisNot yet recruitingNot applicableFirst Affiliated Hospital of Chongqing Medical UniversityNCT07143864Written as Stapokibart
- A Study of Stapokibatrt in Children Subjects With Atopic DermatitisNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07106372Written as Stapokibatrt
- Study of Stapokibatrt in Children Subjects With Atopic DermatitisNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT06956196Written as Stapokibatrt
- A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal PolypsNot yet recruitingPhase 4Beijing Tongren HospitalNCT06801353Written as Stapokibart
- Study of Stapokibart Injection in Patients With Allergic RhinitisRecruitingPhase 2Keymed Biosciences Co.LtdNCT06525597Written as Stapokibart Injection
- A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNot yet recruitingPhase 2/3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06547333Written as CM310
- A Study of CM310 in Subjects With Moderate to Severe AsthmaRecruitingPhase 2/3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05761028Written as CM310
- Study of CM310 in Subjects With Seasonal Allergic RhinitisNot yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06171074Written as CM310
- Study Evaluating the Pharmacokinetics of CM310 in Healthy SubjectsNot yet recruitingPhase 1Keymed Biosciences Co.LtdNCT06171048Written as CM310
- A Study of CM310 in Subjects With Moderate-to-Severe Atopic DermatitisCompletedPhase 2Keymed Biosciences Co.LtdNCT06116565Written as CM310
- Study on the Treatment of Prurigo Nodularis With Stapokibart InjectionCompletedPhase 3Keymed Biosciences Co.LtdNCT06424470Written as Stapokibart
- Study of CM310 in Adolescent Subjects With Atopic DermatisActive, not recruitingPhase 3Keymed Biosciences Co.LtdNCT06495229Written as CM310
- Study of CM310 Injection in Adolescent Subjects With Atopic DermatisCompletedPhase 3Keymed Biosciences Co.LtdNCT06277765Written as CM310
Codes
What other systems call stapokibart · ClinicalTrials.gg INT017129
- UNII (FDA) L2REN9TU2DSTAPOKIBARTOne source FDA
- NCI Thesaurus C188799StapokibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L2REN9TU2D | STAPOKIBART | One source FDA |
| NCI Thesaurus | C188799 | Stapokibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.